摘要
目的 分析环孢素及雄激素联合中药治疗再生障碍性贫血患者的临床效果。方法 选取2019年6月至2023年6月丰城市中医院收治的再生障碍性贫血患者60例进行研究,依据随机数字表法,分为对照组与研究组各30例。对照组给予环孢素及雄激素进行治疗,研究组则在对照组患者基础上联合中药治疗。比对两组患者的治疗有效率,治疗前后的血清炎症因子水平,以及不良反应发生情况。结果 较对照组而言,研究组的治疗有效率更高(P<0.05)。治疗周期结束后,两组的血清肿瘤坏死因子-α(TNF-α)、干扰素γ(IFN-γ)、白介素6(IL-6),以及白介素2(IL-2)的指标水平均降低,研究组的上述指标优于对照组(P<0.05);研究组较对照组不良反应发生率低(P<0.05)。结论 环孢素及雄激素联合中药对再生障碍性贫血患者具有较好的治疗效果,可以降低患者血清炎症因子水平,拥有较高的安全性,具有临床推广价值。
Objective To analyze the clinical efficacy of cyclosporine and androgen combined with traditional Chinese medicine(TCM)in patients with aplastic anemia.Methods 60 cases of aplastic anemia patients admitted to Fengcheng Traditional Chinese Medicine Hospital between June 2019 to June 2023 were selected,were randomly divided into a control group and a research group,each consisting of 30 patients.The control group was treated with cyclosporine and androgen,while the research group received comprehensive treatment that included the same regimen as the control group plus TCM.The treatment response rate,serum levels of inflammatory factors before and after treatment,and incidence of adverse reactions were compared between the two groups.Results The treatment effective rate in the research group was significantly higher than that in the control group(P<0.05).Prior to treatment,there were no statistically significant differences(P>0.05)between the two groups in terms of serum levels of tumor necrosis factor-α(TNF-α),interferonγ(IFN-γ),interleukin 6(IL-6),and interleukin 2(IL-2).However,following the treatment period,these indicators in the research group showed improvement over those in the control group(P<0.05).Moreover,the incidence rate of adverse reactions was lower in the research group compared to the control group(P<0.05).Conclusion The combination therapy of cyclosporine,androgen,and TCM demonstrates a better therapeutic effect for patients with aplastic anemia,effectively reducing their serum inflammatory factor levels.It also exhibits a higher safety profile,making it a promising treatment approach with clinical application value.
作者
谭振胜
TAN Zhensheng(Fengcheng Traditional Chinese Medicine Hospital,Fengcheng Jiangxi 331100,China)
出处
《药品评价》
CAS
2024年第3期375-377,共3页
Drug Evaluation
